Lam DC-L et al (2023) Lung cancer screening in Asia: an expert consensus report. J Thorac Oncol 18(10):1303–1322

PubMed  Google Scholar 

Hill W et al (2023) Lung adenocarcinoma promotion by air pollutants. Nature 616(7955):159–167

PubMed  PubMed Central  CAS  Google Scholar 

Chang JT et al (2018) Temporal trends and geographic patterns of lung cancer incidence by histology in Thailand, 1990 to 2014. J Glob Oncol 4:1–29

PubMed  Google Scholar 

Ruiz-Cordero R, Devine WP (2020) Targeted therapy and checkpoint immunotherapy in lung cancer. Surg Pathol Clin 13(1):17–33

PubMed  Google Scholar 

Zeng Y, Lv X, Du J (2021) Natural killer cell-based immunotherapy for lung cancer: challenges and perspectives (Review). Oncol Rep 46(5):232

PubMed  PubMed Central  CAS  Google Scholar 

Lahiri A et al (2023) Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer 22(1):40

PubMed  PubMed Central  Google Scholar 

Chong X et al (2024) Recent developments in immunotherapy for gastrointestinal tract cancers. J Hematol Oncol 17(1):65

PubMed  PubMed Central  Google Scholar 

Zhao W et al (2022) Colorectal cancer immunotherapy-recent progress and future directions. Cancer Lett 545:215816

PubMed  CAS  Google Scholar 

Wong JKM et al (2023) Weaponizing natural killer cells for solid cancer immunotherapy. Trends Cancer 9(2):111–121

PubMed  CAS  Google Scholar 

Aldarouish M et al (2019) Immunomodulatory effects of chemotherapy on blood lymphocytes and survival of patients with advanced non-small cell lung cancer. Int J Immunopathol Pharmacol 33:2058738419839592

PubMed  PubMed Central  CAS  Google Scholar 

Mazzaschi G et al (2019) The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC. Lung Cancer 127:153–163

PubMed  Google Scholar 

Lau APY, Khavkine Binstock SS, Thu KL (2023) CD47: the next frontier in immune checkpoint blockade for non-small cell lung cancer. Cancers (Basel) 15(21):5229

PubMed  CAS  Google Scholar 

Arrieta O et al (2020) Association between CD47 expression, clinical characteristics and prognosis in patients with advanced non-small cell lung cancer. Cancer Med 9(7):2390–2402

PubMed  PubMed Central  CAS  Google Scholar 

Shimizu A et al (2021) Exosomal CD47 plays an essential role in immune evasion in ovarian cancer. Mol Cancer Res 19(9):1583–1595

PubMed  CAS  Google Scholar 

Xu JF et al (2015) CD47 blockade inhibits tumor progression human osteosarcoma in xenograft models. Oncotarget 6(27):23662–23670

PubMed  PubMed Central  Google Scholar 

Deuse T et al (2021) The SIRPα-CD47 immune checkpoint in NK cells. J Exp Med 218(3): e20200839

PubMed  PubMed Central  CAS  Google Scholar 

Kennedy PR et al (2023) A tri-specific killer engager against mesothelin targets NK cells towards lung cancer. Front Immunol 14:1060905

PubMed  PubMed Central  CAS  Google Scholar 

Felices M et al (2020) Potent cytolytic activity and specific IL15 delivery in a second-generation trispecific killer engager. Cancer Immunol Res 8(9):1139–1149

PubMed  PubMed Central  CAS  Google Scholar 

Vallera DA et al (2016) IL15 trispecific killer engagers (TriKE) make natural killer cells specific to CD33+ targets while also inducing persistence, in vivo expansion, and enhanced function. Clin Cancer Res 22(14):3440–3450

PubMed  PubMed Central  CAS  Google Scholar 

Panaampon J, Kariya R, Okada S (2022) Efficacy and mechanism of the anti-CD38 monoclonal antibody Daratumumab against primary effusion lymphoma. Cancer Immunol Immunother 71(5):1017–1031

PubMed  CAS  Google Scholar 

Schneider CA, Rasband WS, Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9(7):671–675

PubMed  PubMed Central  CAS  Google Scholar 

Oldenborg PA (2004) Role of CD47 in erythroid cells and in autoimmunity. Leuk Lymphoma 45(7):1319–1327

PubMed  CAS  Google Scholar 

Nath PR et al (2018) CD47 expression in natural killer cells regulates homeostasis and modulates immune response to lymphocytic choriomeningitis virus. Front Immunol 9:2985

PubMed  PubMed Central  CAS  Google Scholar 

Moon S et al (2024) Airway epithelial CD47 plays a critical role in inducing influenza virus-mediated bacterial super-infection. Nat Commun 15(1):3666

PubMed  PubMed Central  CAS  Google Scholar 

Liu X et al (2017) Is CD47 an innate immune checkpoint for tumor evasion? J Hematol Oncol 10(1):12

PubMed  PubMed Central  Google Scholar 

Tzatzarakis E et al (2019) The overall potential of CD47 in cancer immunotherapy: with a focus on gastrointestinal tumors. Expert Rev Anticancer Ther 19(11):993–999

PubMed  CAS  Google Scholar 

Hu T et al (2020) Tumor-intrinsic CD47 signal regulates glycolysis and promotes colorectal cancer cell growth and metastasis. Theranostics 10(9):4056–4072

PubMed  PubMed Central  CAS  Google Scholar 

Chen Y et al (2023) The application of HER2 and CD47 CAR-macrophage in ovarian cancer. J Transl Med 21(1):654

PubMed  PubMed Central  CAS  Google Scholar 

Lu J et al (2023) Reprogramming of TAMs via the STAT3/CD47-SIRPα axis promotes acquired resistance to EGFR-TKIs in lung cancer. Cancer Lett 564:216205

PubMed  CAS  Google Scholar 

Jia X et al (2021) CD47/SIRPα pathway mediates cancer immune escape and immunotherapy. Int J Biol Sci 17(13):3281–3287

PubMed  PubMed Central  CAS  Google Scholar 

Li AM et al (2020) New therapeutic approaches to overcoming resistant EGFR exon 20 alterations. Crit Rev Oncol Hematol 151:102990

PubMed  PubMed Central  Google Scholar 

Yun CH et al (2008) The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 105(6):2070–2075

PubMed  PubMed Central  CAS  Google Scholar 

Pao W et al (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2(3):e73

PubMed  PubMed Central  Google Scholar 

Nigro A et al (2019) Enhanced expression of CD47 is associated with off-target resistance to tyrosine kinase inhibitor gefitinib in NSCLC. Front Immunol 10:3135

PubMed  CAS  Google Scholar 

Coënon L, Villalba M (2022) From CD16a biology to antibody-dependent cell-mediated cytotoxicity improvement. Front Immunol 13:913215

PubMed  PubMed Central  Google Scholar 

Wang S et al (2022) Blocking CD47 promotes antitumour immunity through CD103(+) dendritic cell-NK cell axis in murine hepatocellular carcinoma model. J Hepatol 77(2):467–478

PubMed  CAS  Google Scholar 

Tan M et al (2022) Guidance for transfusion management in patients receiving magrolimab therapy (anti-CD47 monoclonal antibody). Intern Med J 52(12):2165–2171

PubMed  CAS  Google Scholar 

de Taeye SW et al (2020) FcγR binding and ADCC activity of human IgG allotypes. Front Immunol 11:740

PubMed  PubMed Central  Google Scholar